

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/196947 A2

(51) International Patent Classification:
C12N 15/861 (2006.01) A61K 31/711 (2006.01)

(21) International Application Number:
PCT/US2024/020571

(22) International Filing Date:
19 March 2024 (19.03.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/491,205 20 March 2023 (20.03.2023) US
63/584,000 20 September 2023 (20.09.2023) US
63/600,153 17 November 2023 (17.11.2023) US

(71) Applicant: SPARK THERAPEUTICS, INC. [US/US];
3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US).

(72) Inventors: ALAM, Suhail; C/o Spark Therapeutics, Inc.,
3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). BIFERI, Maria, Grazia; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). COHEN, Daniel; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). EVANS, James, Perry; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). KHATIWADA, Apeksha; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). MCBRIDE, Jodi; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US). RAMSBURG, Elizabeth; C/o Spark Therapeutics, Inc., 3737 Market Street, Suite 1300, Philadelphia, PA 19104 (US).

(74) Agent: HEBER, Sheldon et al.; ICE MILLER LLP, 1735
Market Street, Suite 3900, Philadelphia, PA 19103 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: PPT1 GENE THERAPY

(57) Abstract: The present invention features PPT1 polypeptides and encoding nucleic acid constructs. Uses of the polypeptides and encoding nucleic acid constructs include producing PPT1 polypeptides, increasing PPT1 activity in a subject; and treating a PPT1 related disorder, such as CLN1 disease in a subject.

WO 2024/196947 A2